Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin

Phytotherapy Research

Volumn 24, Issue 2, 2010, Pages 219-224

  Lv, Lin ^a   Wu, Shao Yu ^a   Wang, Guang Fa ^a   Zhang, Jia Jie ^a   Pang, Jian Xin ^a   Liu, Zhong Qiu ^a   Xu, Wei ^a   Wu, Shu Guang ^a   Rao, Jin Jun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Astragaloside IV; Glucose 6 phosphatase; Glycogen phosphorylase; Hepatic glucose regulating enzymes; Hypoglycemic agents; Type 2 diabetes

Indexed keywords

ASTRAGALOSIDE IV; CHOLESTEROL; GLUCOSE; GLUCOSE 6 PHOSPHATASE; GLYCOGEN PHOSPHORYLASE; INSULIN; MESSENGER RNA; STREPTOZOCIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG DOSE INCREASE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; INSULIN BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DRUGS, CHINESE HERBAL; GLUCOSE-6-PHOSPHATASE; GLYCOGEN PHOSPHORYLASE; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; SAPONINS; STREPTOZOCIN; TRIGLYCERIDES; TRITERPENES;

MUS;

EID: 75849132824     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2915     Document Type: Article

References (32)

1. Agius L. 2007. New hepatic targets for glycaemic control in diabetes. Best Pract Res Clin Endocrinol Metab 21: 587-605.
2. Alegre M, Ciudad CJ, Fillat C et al. 1988. Determination of glucose-6-phosphatase activity using the glucose dehydrogenase-coupled reaction. Anal Biochem 173: 185-189.
3. American Institute of Nutrition. 1977. Report of the American Institute of Nutrition Ad Hoc Committee on Standards for Nutritional Studies. American Institute of Nutrition: USA, 1340-1348.
4. Barf T. 2004. Intervention of hepatic glucose production. Small molecule regulators of potential targets for type 2 diabetes therapy. Mini Rev Med Chem 4: 897-908.
5. Bollen M, Keppens S, Stalmans W. 1998. Specific features of glycogen metabolism in the liver. Biochem J 336: 19-31.
6. Chen D, Wang MW. 2005. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 7: 307-317.
7. Freeman S, Bartlett JB, Convey G. 2006. Sensitivity of glycogen phosphorylase isoforms to indole site inhibitors is markedly dependent on the activation state of the enzyme. Br J Pharmacol 149: 775-785.
8. Gregus Z, Nemeti B. 2007. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors. Toxicol Sci 100: 44-53.
9. Jiang B, Yang Y, Jin H. 2008. Astragaloside IV attenuates lipolysis and improves insulin resistance induced by TNFalpha in 3T3-L1 adipocytes. Phytother Res 22: 1434-1439.
10. Jung UJ, Lee MK, Park YB. 2006. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem Cell Biol 38: 1134-1145.
11. Kuang Y, Schomisch SJ, Chandramouli V et al. 2006. Hexokinase and glucose-6-phosphatase activity in woodchuck model of hepatitis virus-induced hepatocellular carcinoma. Comp Biochem Physiol C Toxicol Pharmacol 143: 225-231.
12. Kurukulasuriya R, Link JT, Madar DJ. 2003. Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production. Curr Med Chem 10: 123-153.
13. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)). Method 4: 402-408.
14. Lowry OH, Schulz DW, Passonneau JV. 1967. The kinetics of glycogen phosphorylases from brain and muscle. J Biol Chem 242: 271-280.
15. Luo J, Quan J, Tsai J. 1998. Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 47: 663-668.
16. Luo Y, Qin Z, Hong Z. 2004. Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia. Neurosci Lett 363: 218-223.
17. Maiese K, Chong ZZ, Shang YC. 2007. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 14: 1729-1738.
18. McCormack JG, Westergaard N, Kristiansen M. 2001. Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. Curr Pharm Des 7: 1451-1474.
19. Nordlie RC, Arion WJ. 1965. Liver microsomal glucose 6- phosphatase, inorganic pyrophosphatase, and pyrophosphate-glucose phosphotransferase. 3. Associated nucleoside triphosphate- and nucleoside diphosphate-glucose phosphotransferase activities. J Biol Chem 240: 2155-2164.
20. Nordlie RC, Arion WJ. 1966. Glucose-6-phosphatase. Methods Enzymol 9: 619-625.
21. Nordlie RC, Arion WJ, Glende EA Jr. 1965. Liver microsomal glucose 6-phosphatase, inorganic pyrophosphatase, and pyrophosphate-glucose phosphotransferase. IV. Effects of adrenalectomy and cortisone administration on activities assayed in the absence and presence of deoxycholate. J Biol Chem 240: 3479-3484.
22. Nordlie RC, Foster JD, Lange AJ. 1999. Regulation of glucose production by the liver. Annu Rev Nutr 19: 379-406.
23. Onda K, Suzuki T, Shiraki R. 2008. Synthesis of 5-chloro-N-aryl- 1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a. Bioorg Med Chem 16: 5452-5464.
24. Petersen KF, Laurent D, Rothman DL. 1998. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest 101: 1203-1209.
25. Reed MJ, Scribner KA. 1999. In vivo and in vitro models of type 2 diabetes in pharmaceutical drug discovery. Diabetes Obes Metab 1: 75-86.
26. Report of the American Institute of Nutrition Ad Hoc Commitee on Standards for Nutritional Studies. J. Nutr 107: 1340-1348.
27. Rios JL, Waterman PG. 1998. A review of the pharmacology and toxicology of Astragalus. Phytother Res 11: 411-418.
28. Wallis MG, Appleby GJ, Youd JM. 1999. Reduced glycogen phosphorylase activity in denervated hindlimb muscles of rat is related to muscle atrophy and fibre type. Life Sci 64: 221-228.
29. Wang S, Li J, Huang H. 2009. Anti-hepatitis b virus activities of astragaloside IV isolated from radix astragali. Biol Pharm Bull 32: 132-135.
30. Yu J, Zhang Y, Sun S. 2006. Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats. Can J Physiol Pharmacol 84: 579-587.
31. Zhang WJ, Hufnagl P, Binder BR et al. 2003. Antiinflammatory activity of astragaloside IV is mediated by inhibition of NFkappaB activation and adhesion molecule expression. Thromb Haemost 90: 904-914.
32. Zhang ZC, Li SJ, Yang YZ. 2007. Effect of astragaloside on cardiomyocyte apoptosis in murine coxsackievirus B3 myocarditis. J Asian Nat Prod Res 9: 145-151.